Admedus : Waiver from Listing Rule 10.13.5

ADMEDUS LIMITED ABN 35 088 221 078

REGISTERED OFFICE:

26 Harris Road Malaga Western Australia 6090

F +61 (0)8 9266 0199

ASX ANNOUNCEMENT

E info.au@admedus.com

www.admedus.com

Brisbane, Australia 7 October, 2016

Admedus (ASX:AHZ) announced today that ASX Limited has, on 12 September 2016 granted a waiver from listing rule 10.13.5 to the extent necessary to permit the Company's notice of annual general meeting dated 15 September 2016 (the "Notice") to approve the issue of a maximum of $54,120 worth of shares to Mr Michael Bennett, a maximum of $105,573 worth of shares to Mr Wayne Paterson, a maximum of $22,000 worth of shares to Mr John Seaberg, a maximum of $22,000 worth of shares to Mr Mathew Ratty ("Directors"), in each case in lieu of directors' fees, not to include an issue price, subject to the following conditions:

1. the Notice states that the Remuneration Shares will be issued to the Directors at an issue price which is equal to the 5 day volume weighted average price of Admedus' shares immediately before the issue date;

2. the Remuneration Shares to be issued within one month after the date of the annual general meeting;

3. the Notice contains the full terms and conditions of the Remuneration Shares;

4. Admedus releases the terms of the waiver to the market at the same time as the Notice is released to the market by way of a separate announcement; and

5. Admedus' annual report for any period during which the shares are issued to the Directors, discloses details of the number of shares that were issued to each of them, including the percentage Admedus' issued capital represented by those shares.

On 13 October 2015 the Company announced that ASX Limited had granted a waiver on similar terms to the above in respect of the notice of annual general meeting dated 24 September 2015.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100

FTI Consulting

Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com